Therapeutic implications of CD1d expression and tumor-infiltrating macrophages in pediatric medulloblastomas
- 13 August 2014
- journal article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 120 (2) , 293-301
Abstract
Immunobiology of medulloblastoma (MB), the most common malignant brain tumor in children, is poorly understood. Although tumor cells in some MBs were recently shown to express CD1d and be susceptible to Vα24-invariant natural killer T (NKT)-cell cytotoxicity, the clinical relevance of CD1d expression in MB patients remains unknown. We investigated the expression of CD1d in pediatric MBs and correlated with molecular and clinical characteristics. Specifically, we explored if NKT cell therapy can be targeted at a subset of pediatric MBs with poorer prognosis. Particularly, infantile MBs have a worse outcome because radiotherapy is delayed to avoid neurocognitive sequelae. Immunohistochemistry for CD1d was performed on a screening set of 38 primary pediatric MBs. Gene expression of the membrane form of M2 macrophage marker, CD163, was studied in an expanded cohort of 60 tumors. Outcome data was collected prospectively. Thirteen of 38 MBs (34.2 %) expressed CD1d on immunohistochemistry. CD1d was expressed mainly on MB tumor cells, and on some tumor-associated macrophages. Majority (18/22, 82 %) of non sonic-hedgehog/Wingless-activated MBs (group 3 and 4) were CD1d-negative (p = 0.05). A subset of infantile MBs (4/9, 44.4 %) expressed CD1d. Macrophages infiltrating MB expressed CD163 apart from CD1d. Molecular subtypes demonstrated statistical differences in CD163 expression, SHH-tumors were the most enriched (p = 0.006). Molecular and clinical subtypes of pediatric MB exhibit distinct differences in CD1d expression, which have important therapeutic implications. High CD1d expression in infantile MBs offers potential new immunotherapeutic treatment with NKT cell therapy in infants, where treatment is suboptimal due delayed radiotherapy.Keywords
This publication has 50 references indexed in Scilit:
- Molecular subgroups of medulloblastoma: the current consensusActa Neuropathologica, 2011
- Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: Results of the first UKCCSG/SIOP CNS 9204 trialEuropean Journal of Cancer, 2010
- Invariant TCR Rather Than CD1d Shapes the Preferential Activities of C-Glycoside Analogues Against Human Versus Murine Invariant NKT CellsThe Journal of Immunology, 2009
- Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophagesJournal of Clinical Investigation, 2009
- Aggressive Infantile Embryonal TumorsJournal of Child Neurology, 2008
- The making of NKT cellsNature Immunology, 2008
- Cancer-related inflammationNature, 2008
- Altered macrophage differentiation and immune dysfunction in tumor developmentJournal of Clinical Investigation, 2007
- Increased Intratumor Vα24-Positive Natural Killer T Cells: A Prognostic Factor for Primary Colorectal CarcinomasClinical Cancer Research, 2005
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958